iBio, Inc. and GE Healthcare Form New Global Alliance
iBio, Inc. (NYSE MKT: IBIO), and GE Healthcare, the healthcare business of GE (NYSE: GE), announced a new global alliance to commercialize plant-based technologies for the manufacture of biopharmaceuticals and vaccines. The alliance builds on the existing development and marketing agreement between the two companies announced in 2010 and combines iBio’s innovative plant-based vaccine manufacturing platform, iBioLaunch™, with GE Healthcare’s world-class capabilities in start-to-finish technologies for biopharmaceutical manufacturing. iBio’s research and development collaborator, Fraunhofer USA Center for Molecular Biotechnology (CMB) will continue to play a key role in advancing the iBioLaunch platform. Financial terms were not disclosed.
GE Healthcare Unveils Exclusive 360 Degree Virtual Tour of London 2012 Olympic Village Polyclinic
GE Healthcare today unveils a ‘one of a kind’ virtual video tour of the London 2012 Olympic Village Polyclinic, allowing viewers to see inside an Olympic Village Polyclinic for the first time and learn more about the broad range of medical imaging technologies in use from GE Healthcare. Interact with an innovative 360 degree video experience here
Ogden Regional Medical Center Grows Surgical Capacity, Improves OR Efficiency with GE Healthcare Performance Solutions
GE Healthcare Performance Solutions, a unit of GE Healthcare (NYSE: GE), and Ogden Regional Medical Center, a 239-bed Level II trauma and certified stroke center in the Salt Lake City area, announced the successful results of a perioperative services improvement program, implemented to improve surgical capacity at Ogden Regional. The project – which included the strategic analysis of Ogden Regional’s OR scheduling processes using GE’s Block Optimizer software as well as the establishment of new OR governance procedures – resulted in notable growth in surgical cases and increased ease of scheduling procedures.
GE Healthcare provides state-of-the-art imaging technology to the anti-doping team at London 2012
A state-of-the-art product from the Healthcare division of the London 2012 Olympic Games sponsor, GE will play a key role in the fight against doping at the London 2012 Olympic Games and Paralympic Games this summer. GE Healthcare Life Sciences, a $1.8 billion division of GE Healthcare, provides technologies and tools for basic research into cells and proteins, drug discovery research, and large-scale manufacturing of biopharmaceuticals. Its ImageQuant™ LAS4000, a biomolecular imager, is a crucial part of the testing process for recombinant erythropoietin (EPO) – a performance enhancing drug that can be used to boost the number of red blood cells enabling vastly improved oxygen flow, increasing an athlete's endurance. The EPO test will be one of many undertaken during the Games at the new Anti-Doping Science Centre in Harlow, Essex – the most advanced drug testing laboratory in the history of the Olympic Games. GlaxoSmithKline (GSK) is the Official Laboratory Services Provider for the London 2012 Olympic and Paralympics Games and will provide facilities and equipment to enable expert analysts from King’s College London to independently operate a World Anti-Doping Agency (WADA) accredited laboratory during the London 2012 Games.
Final Phase 3 Results for GE Healthcare Investigational Imaging Agent Flutemetamol Presented at Alzheimer’s Association International Conference®
GE Healthcare today announced the final results from a phase 3 study of the investigational PET amyloid imaging agent, [18F]flutemetamol in terminally ill patients who had agreed to undergo postmortem brain autopsy.[ i ] The data showed strong concordance (sensitivity and specificity) between [18F]flutemetamol PET images and beta amyloid brain histopathology. These data confirm the potential of [18F]flutemetamol as an imaging agent to detect beta amyloid plaque, a pathology associated with Alzheimer’s disease (AD), in living patients.
] IkonomovichM, Buckley C, Smith A et al. [18F]Flutemetamol injection PET images reflect brain amyloid levels. Data presented at Alzheimer's Association® International Conference 2012 (AAIC 2012), Vancouver, BC, Canada.
[ii] Dementia: Hope Through Research. National Institute of Neurological Disorders and Stroke website.http://www.ninds.nih.gov/disorders/dementias/detail_dementia.htm. Accessed July 13, 2011.